Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers

International Journal of Clinical Oncology

Volumn 21, Issue 2, 2016, Pages 254-261

  Enomoto, Yukie ^a   Morimoto, Takashi ^b   Nishimukai, Arisa ^a   Higuchi, Tomoko ^a   Yanai, Ayako ^a   Miyagawa, Yoshimasa ^a   Murase, Keiko ^a   Imamura, Michiko ^a   Takatsuka, Yuichi ^a   Nomura, Takashi ^b   Takeda, Masashi ^b   Watanabe, Takahiro ^a   Hirota, Seiichi ^a   Miyoshi, Yasuo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Yao Municipal Hospital   (Japan)

Author keywords

Breast cancer; Ki67; Neoadjuvant chemotherapy; Progesterone receptor

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL EVALUATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEASUREMENT; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PREMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84940702374     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0897-1     Document Type: Article

References (29)

1. Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96–102
2. Rouzier R, Pusztai L, Delaloge S et al (2005) Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23:8331–8339
3. Chaturvedi S, McLaren C, Schofield AC et al (2005) Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast? Breast Cancer Res Treat 93:151–158
4. Abrial SC, Penault-Llorca F, Delva R et al (2005) High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94:255–263
5. Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037–1044
6. Mazouni C, Kau SW, Frye D et al (2007) Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18:874–880
7. von Minckwitz G, Blohmer JU, Costa SD et al (2013) Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 31:3623–3630
8. Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422
9. Romero A, García-Sáenz JA, Fuentes-Ferrer M et al (2013) Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. Ann Oncol 24:655–661
10. Cockburn A, Yan J, Rahardja D et al (2014) Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer. Hum Pathol 45:249–258
11. Miller M, Ottesen RA, Niland JC et al (2014) Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol 21:3317–3323
12. Bottini A, Berruti A, Bersiga A et al (2001) Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 85:1106–1112
13. Makris A, Powles TJ, Allred DC et al (1999) Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 53:51–59
14. Chang J, Ormerod M, Powles TJ et al (2000) Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89:2145–2152
15. Burcombe R, Wilson GD, Dowsett M et al (2006) Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res 8:R31
16. von Minckwitz G, Schmitt WD, Loibl S et al (2013) Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 19:4521–4531
17. Zhang N, Moran MS, Huo Q et al (2011) The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Investig 29:594–598
18. Pagani O, O’Neill A, Castiglione M et al (1998) Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632–640
19. Swain SM, Jeong JH, Geyer CE Jr et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053–2065
20. Japanese Breast Cancer Society (2012) General rules for clinical and pathological recording of breast cancer, 17th edn. Kanehara & Co., Ltd, Tokyo
21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
22. Jones RL, Salter J, A’Hern R et al (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116:53–68
23. Tanei T, Shimomura A, Shimazu K et al (2011) Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 37:155–161
24. Miller TW, Balko JM, Fox EM et al (2011) ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1:338–351
25. Guix M, Granja Nde M, Meszoely I et al (2008) Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 26:897–906
26. Dave B, Migliaccio I, Gutierrez MC et al (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29:166–173
27. Ellis MJ, Suman VJ, Hoog J et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol 29:2342–2349
28. Navolanic PM, Steelman LS, McCubrey JA (2003) EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 22:237–252
29. Lewis-Wambi JS, Jordan VC (2009) Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11:206